Q4 23 EPS
$-0.77
BEAT +41.67%
Est. $-1.32
Q4 23 Revenue
$439.7M
MISS 0.10%
Est. $440.1M
vs S&P Since Q4 23
+53.6%
BEATING MARKET
ALNY +97.9% vs S&P +44.3%
Full Year 2023 Results
FY 23 EPS
$-3.52
MISS 1.44%
Est. $-3.47
FY 23 Revenue
$1.83B
MISS 0.02%
Est. $1.83B
Market Reaction
Did ALNY Beat Earnings? Q4 2023 Results
Alnylam Pharmaceuticals closed out 2023 with a stronger-than-expected fourth quarter, posting a non-GAAP loss of $0.77 per share against a consensus estimate of $-1.32, a beat of 41.67% that reflected meaningfully tighter losses than analysts had ant… Read more Alnylam Pharmaceuticals closed out 2023 with a stronger-than-expected fourth quarter, posting a non-GAAP loss of $0.77 per share against a consensus estimate of $-1.32, a beat of 41.67% that reflected meaningfully tighter losses than analysts had anticipated. Revenue of $439.72 million, up 31.3% year-over-year, came in fractionally below the $440.15 million consensus estimate, a miss of just 0.10% that did little to overshadow the broader momentum. The primary engine behind that top-line growth was AMVUTTRA, which generated $175.25 million in Q4 net product revenues as the RNAi therapy continued to gain traction in the hATTR amyloidosis with polyneuropathy market, helping push full-year global net product revenues to $1.24 billion. Looking ahead, management guided 2024 combined net product revenues of $1.40 billion to $1.50 billion, representing 13% to 21% growth, with investors closely watching for HELIOS-B Phase 3 topline results for vutrisiran in ATTR cardiomyopathy, expected in late June or early July.
Key Takeaways
- • Strong AMVUTTRA uptake driving TTR franchise growth of 33% YoY in Q4
- • Increased patient enrollment across all four commercial medicines, surpassing 5,000 patients globally
- • Collaboration revenue growth of 305% for full year driven by Roche partnership and Regeneron milestone
- • Total net product revenue growth of 32% in Q4 and 39% for full year 2023
ALNY YoY Financials
Q4 2023 vs Q4 2022, source: SEC Filings
ALNY Revenue by Segment
With YoY comparisons, source: SEC Filings
“2023 was a year of strong execution at Alnylam. We delivered robust product revenue growth across our four wholly-owned commercial medicines, with $1.24 billion in global net product revenues, and achieved over 5,000 patients now being treated with an Alnylam commercial medicine. We also extended our leadership in RNAi with the first clinical demonstration of gene silencing in the human brain using an RNAi therapeutic, strengthened our business for the future through a landmark partnership with Roche and delivered solid financial performance.”
— Yvonne Greenstreet, Q4 2023 Earnings Press Release
ALNY Earnings Trends
ALNY vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ALNY EPS Trend
Earnings per share: estimate vs actual
ALNY Revenue Trend
Quarterly revenue: estimate vs actual
ALNY Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $1.99 | — | $1.17B | +4.53% |
| Q4 25 BEAT FY | $1.24 | $1.25 | +0.81% | $1.10B | -5.22% |
| FY Full Year | $4.79 | $5.08 | +6.03% | $3.71B | -1.60% |
| Q3 25 BEAT | $1.75 | $2.90 | +66.12% | $1.25B | +28.22% |
| Q2 25 BEAT | $0.15 | $0.32 | +119.63% | $773.7M | +16.79% |
| Q4 23 BEAT FY | $-1.32 | $-0.77 | +41.67% | $439.7M | -0.10% |
| FY Full Year | $-3.47 | $-3.52 | -1.44% | $1.83B | -0.02% |